Researchers determined that gPALB2 may be a promising biomarker for talazoparib response.
Patients with diabetes, hypercholesterolemia, or CAD had 23.9%, 11.4%, and 19.2% increased costs, respectively, versus those without risk factors for CVD.
The authors found that BRCA1-positive patients who became pregnant had improved disease-free survival, although there was no improvement in overall survival.
Rates of 2-year OS were 51% and 37% in the subgroup of patients with detectable tumor levels of PD-L1 who received atezolizumab and placebo, respectively.
Rates of grade 3 diarrhea were 2-fold higher for patient receiving neratinib vs lapatinib, although fewer patients discontinued neratinib due to a treatment-related AE.
Antitumor activity was also observed in the subgroup of patients receiving pyrotinib monotherapy following disease progression on placebo plus capecitabine.
This is the first study to demonstrate a statistically significant improvement in OS with the addition of a CDK4/6 inhibitor to endocrine therapy.
Evidence of HER2 intratumor heterogeneity was found in 10% of the patients enrolled in this study.
In this patient subset, BEV+PEM maintenance therapy after CAR+PEM+BEV induction therapy “could have survival benefits.”
Adding pemetrexed-carboplatin chemotherapy to gefitinib significantly prolonged PFS and OS but also increased toxicity.
RELAY is a multicenter, double-blind, randomized clinical trial that enrolledin patients who had no prior treatment for 1L epidermal growth factor receptor (EGFR)-mutant metastatic non−small cell lung cancer.
The data suggest that OS may actually be worse for patients receiving pazopanib following surgery for metastatic RCC.
The expression of interferon-related genes in tumor specimens was associated with response to neoadjuvant immune checkpoint inhibitor-based therapy.
An analysis of patients in the ZUMA-1 trial found that day 28 minimal residual disease levels could identify patients at risk for early progression.
In a study of men with metastatic castration-sensitive prostate cancer, apalutamide plus androgen deprivation therapy (ADT) decreased the risk of death by 33% compared with placebo plus ADT.
In a phase 2 study, patients with metastatic urothelial carcinoma who had stable disease on first-line platinum-based chemotherapy experienced a delay in disease progression when switched to pembolizumab.
In a head-to-head comparative study involving PCa patients with early biochemical recurrence following radical surgery, PSMA PET/CT had significantly higher cancer detection rates than fluciclovine PET/CT.
Nodal and metastatic prostate cancer at diagnosis increased after 2008, when the USPSTF recommended against PSA screening for men aged 75 or older, and again when it expanded the recommendation for all men.
“Nonrelapse mortality needs to be defined prospectively for all ongoing CAR-T studies,” said the researchers.
The Fc fragment of therapeutic antibodies is believed to recognize specific receptors on immune cells and mediate immune functions through this interaction.